Early proactive therapeutic drug monitoring with ustekinumab therapy in pediatric Crohn's disease: data from the prospective Canadian children IBD network.
Children <40 kg required more IV ustekinumab (median 9 mg/kg; 250 mg/m<sup>2</sup>) to achieve similar week 8 levels as children ≥40kg receiving conventional adult 6 mg/kg weight-tiered induction. Higher week 8 levels were associated with favorable later outcomes.
Authors
- Amanda Ricciuto (ORCID: https://orcid.org/0000-0001-9538-3005)
- Nicholas Carman
- T Walters
- Jennifer deBruyn (ORCID: https://orcid.org/0000-0001-6812-7620)
- Rilla Schneider (ORCID: https://orcid.org/0000-0002-0521-5129)
- Hayley E. McKay (ORCID: https://orcid.org/0000-0002-7882-3328)
- P Church
- Ayub Shaikh
- Wael El-Matary
- Anthony R Otley
- Eytan Wine
- Anne M Griffiths
- Eileen Crowley
- Hien Q Huynh
- David R Mack
Institutions
- Western University (CA)
- Dalhousie University (CA)
- University of Alberta (CA)
- University of Toronto (CA)
- Children's Hospital of Eastern Ontario (CA)
- Montreal Children's Hospital (CA)
- London Health Sciences Centre (CA)
- Hospital for Sick Children (CA)
- Alberta Children's Hospital (CA)
- Children's Hospital Research Institute of Manitoba (CA)
- SickKids Foundation (CA)
- Children's Hospital of Western Ontario (CA)
Publication Details
- Journal
- PubMed
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1093/crocol/otag019
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00